Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
CAR-T
Pharma
A $410M obesity debut, Legend, BeiGene and more—Fierce Pharma Asia
Three Chinese obesity assets are featured in Verdiva's $410 million debut. Experts analyzed the buyout prospects of Legend and BeiGene. Plus more.
Angus Liu
Jan 10, 2025 9:00am
Autolus enters CAR-T race with FDA approval for Aucatzyl
Nov 11, 2024 11:30am
FDA revisits CAR-T boxed warning on secondary cancers: Marks
Nov 1, 2024 10:30am
Lilly, Gilead-Yuhan, Leqembi—Fierce Pharma Asia
Oct 18, 2024 8:20am
J&J, Legend's Carvykti shows 45% survival benefit in myeloma
Sep 30, 2024 9:50am
BMS, 2seventy scrap Abecma trial in first-line multiple myeloma
Sep 25, 2024 10:52am
